Member Info for Brand

I think so too, who in their right mind would even consider selling a single share at this point?!

If governments are going to directly buy your product, you've at max got 75-100 accounts to manage. It's easy enough to expand your commercial team to meet demand.

Local service providers can provide in situ support a la Ashfield Engage or similar.

Every country that hosted sprinter has the potential for local licensed production and distribution, with the funding coming from government pre-orders. Others may be queuing at the gate

Even the hardware comes from an external partner.

So what value would a big pharma partner add?

Uncle Joe Biden was also the senator for Delaware for some 30 odd years.

Some learned commentary on this paper via twitter

https://twitter.com/julienpotet/status/1483100239858966528?t=DsnuU9A5LRF_6wo4-fFxpw&s=19

Pretty clever putting the job listings on there if your expecting a whole bunch of traffic in the near future.

Tell me your results as the good without telling me your results are good...

SNG: hold my beer.

Missed one - Rocket Fuel Manger (US based)

Let's go :)

I don't know if we ever got details of exactly what the relationship is between SNG and IQVIA, but just had a look on LinkedIn and yes, they are hiring for dozens of sales roles, with the jobs listed in the last week.

Abstract

SARS-CoV-2 infection fatality rate (IFR) doubles with every five years of age from childhood onward. Circulating autoantibodies neutralizing IFN-a, IFN-?, and/or IFN-ß are found in ~20% of deceased patients across age groups. In the general population, they are found in ~1% of individuals aged 20-70 years and in >4% of those >70 years old. With a sample of 1,261 deceased patients and 34,159 uninfected individuals, we estimated both IFR and relative risk of death (RRD) across age groups for individuals carrying autoantibodies neutralizing type I IFNs, relative to non-carriers. For autoantibodies neutralizing IFN-a2 or IFN-?, the RRD was 17.0[95% CI:11.7-24.7] for individuals under 70 years old and 5.8[4.5-7.4] for individuals aged 70 and over, whereas, for autoantibodies neutralizing both molecules, the RRD was 188.3[44.8-774.4] and 7.2[5.0-10.3], respectively. IFRs increased with age, from 0.17%[0.12-0.31] for individuals <40 years old to 26.7%[20.3-35.2] for those =80 years old for autoantibodies neutralizing IFN-a2 or IFN-?, and from 0.84%[0.31-8.28] to 40.5%[27.82-61.20] for the same two age groups, for autoantibodies neutralizing both molecules. Autoantibodies against type I IFNs increase IFRs, and are associated with high RRDs, particularly those neutralizing both IFN-a2 and -?. Remarkably, IFR increases with age, whereas RRD decreases with age. Autoimmunity to type I IFNs appears to be second only to age among common predictors of COVID-19 death.

New paper just publicly shared on the sng Reddit board

https://www.researchsquare.com/article/rs-1225906/v1

Looks to be a huge number of names and institutions on there. A good read.

Sakura has definitely been on of my faves

Thanks Matml, it's a good point re activ P3 and the breathless at home. I would think 'breathlessness' is one of the first indications of 'moderate' covid over 'mild'

Thanks Matml, I completely agree and imo this is what separates SNG from so many other treatments, and why It's such a potential game changer (it also makes it much easier to justify the cost)

But is it not also right that we haven't seen a large enough trial to show SNGs effectiveness in mild to moderate patients? And that while data to date may show the most benefit Vs the breathless cohort, there is still every chance it will show benefit Vs mild to moderate patients as well? The home trial didn't show statistical significance, but there was some benefit Vs placebo, and of course Activ progressed to P3

From what I recall, the A2P3 trial is meant to treat 800 patients w SNG, which given everything we have learned about inhaled interferon beta, I believe will show strong efficacy.

This is all imho, but from what we've seen in the peer review studies that have been published since progression to A2P3, it's been well established that INFb is 'potent' (SNGs words) vs SARS-CoV-2.

What data from both Activ and Sprinter should tell us is the 'window' for treatment with SNG001. Given the data we've seen so far, it's most likely is that it is effective from first infection to when the virus has cleared the body. I think a big question is, is it worth £2k a treatment from first infection when most people recover on their own? Perhaps a lower dosage or number of treatments would be in order from first infection, this is the kind of data we should be hoping for from ACTiV imv.

The journal of immunology study mentioned it's potential as a prophylactic, tho I have seen that the INFa nasal spray that was utilised in China has had issues with inflammation in the nostrils and sinuses - it may be a bit extreme to have everybody huffing on INFb everyday to ward off the virus, but it could certainly be helpful in an outbreak scenario.

So I don't think is a scenario where it is one or the other, what we should learn between the two studies is the range (for lack of a better word) for SNG.

GLA

I have indeed. Incredibly informative and very interesting that it was released, along with RMs, the week when the market would expect P3 data to be unblinded.

Watch this...

https://www.webmd.com/coronavirus-in-context/video/richard-marsden

Andybe - (aka NDN) wants to tell you posts on this board mean nothing, but when I posted a tweet of mine on here a while back it had over 4000 views, which is about 10 X what my posts usually get.

NDN is going for a promotion to 'Senior Influencer'

Going what we have seen here in the UK, I think it's likely A2P3 will mirror what we currently have w the Pfizer and Merck drugs, where SNG receives EUA on the back of sprinter + Activ results and is 'trialed' in situ.

I quite like sharedealers predictions. Has absolutely nailed the last few.

Excellent find, thank you as always Matterhorn.